Stellarex drug-coated 0.035" angioplasty balloon

The clear DCB choice

Every patient deserves Stellarex

Learn more

Top-tier outcomes with the lowest therapeutic drug dose in all patients—common to complex

Choose efficacy

Stellarex exhibits consistent two-year patency across trials, even in the most complex PAD cases. Stellarex is the only DCB reported to have durable patency at 2 years in severely calcified lesions.

75.2%

2 yr patency In common
patients18

72.1%

2 yr patency In complex
patients35

67.8%

2 yr patency In severely
calcified lesions35

The Stellarex difference

Stellarex’s unique coating composition, EnduraCoat technology, combines amorphous and small-to-large crystalline paclitaxel with polyethylene glycol (PEG) excipient. The result is efficient drug transfer, effective tissue residency, high coating durability and minimal particulate loss.

About the coating

Choose low particulate

Particulate loss is associated with an increased risk of downstream embolization. In bench tests, Stellarex demonstrated 79% less particulate loss than In.Pact.9

Compare particulate

See more Stellarex clinical evidence

Download brochure